Pharmafile Logo
Pharmafocus logo
Advanced Search

ofev

Showing 13 posts of 13 posts found.

boehringer_biberach_germany_copy

Boehringer’s TKI inhibitor Ofev gets FDA approval for chronic fibrosing interstitial lung diseases with a progressive phenotype

March 10, 2020
Manufacturing and Production, Sales and Marketing Boehringer, FDA, ofev, pharma

The FDA has green-lit Boehringer Ingelheim’s multi-targeted tyrosine kinase inhibitor Ofev (nintedanib) in the treatment of chronic fibrosing interstitial lung …

News
boehringer_biberach_germany_copy

Boehringer’s Ofev scores first-of-its-kind FDA approval in rare lung disease

September 10, 2019
Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, FDA, US, lungs, ofev, pharma, rare disease

Boehringer Ingelheim’s Ofev (nintedanib) capsules have now secured marketing authorisation in the US, it has emerged, for the treatment of …

News
boehringer_good

Boehringer launches IPF initiatives

February 29, 2016
Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Esbriet, Roche, idiopathic pulmonary fibrosis, ofev

Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …

News
boehringer_good

Boehringer’s OFEV slows IPF disease progression by half in trials

February 26, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, IPF, ofev

Boehringer Ingelheim has revealed pooled analysis data from three trials, showing that its drug OFEV significantly reduces the risk of …

News

Boehringer widens IPF drug’s reach

May 18, 2015
Sales and Marketing Boehringer, Esbriet, ats, brett wells, nintedanib, ofev

Boehringer Ingelheim has highlighted new data for its idiopathic pulmonary fibrosis (IPF) treatment Ofev in a Phase II study on …

News

Boehringer assures future growth following sales drop

April 23, 2015
Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results

Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …

News
Ofev image

Boehringer eyes Ofev success in IPF and beyond

March 16, 2015
Sales and Marketing Boehringer, Esbriet, Roche, ingelheim, inpulsis, ipd, ofev

Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet …

News
Ofev image

Boehringer gains EU approval for Ofev

January 19, 2015
Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev

The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …

News
BI image

Boehringer’s lung cancer drug Vargatef sees EU approval

November 28, 2014
Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef

Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …

News
BI image

CHMP nods several drugs through

November 24, 2014
Sales and Marketing Boehringer, CHMP, EMA, Esbriet, FDA, Sanofi, nintedanib, ofev

Ten new medicines have been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP), among …

News

Growing IPF drugs market evident at ERS Congress

November 3, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ERS, Esbriet, IPF, elf, european respiratory society, ofev

Arriving in Germany for this year’s European Respiratory Society (ERS) International Congress 2014, what awaited Pharmafile at the Ausgang was …

Feature
Boehringer image

Boehringer seeks more indications for IPF drug

October 22, 2014
Research and Development, Sales and Marketing Boehringer, IPF, NSCLC, colectoral, crc, nintedanib, ofev

Boehringer Ingelheim’s nintedanib has entered Phase III studies for the treatment of colorectal cancer (CRC), which could add to the …

News
Boehringer image

Boehringer and Roche IPF drugs win FDA approval

October 16, 2014
Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, FDA, IPF, InterMune, Roche, US, lung scarring, lungs, ofev

The FDA has approved both Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of the fatal lung …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024